title: Experience with intravenous immunoglobulin in severe childhood atopic dermatitis.
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ozen
authors.forename: Safa
authors.initials: S
authors.lastname: Baris
authors.forename: Elif
authors.initials: E
authors.lastname: Karakoc Aydiner
authors.forename: Deniz
authors.initials: D
authors.lastname: Yucelten
authors.forename: Nerin
authors.initials: N
authors.lastname: Nadir Bahceciler
mesh_terms: D000286:Administration, Sublingual; D000293:Adolescent; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000009:adverse effects / Q000276:immunology; D002648:Child; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D003888:Desensitization, Immunologic; D018450:Disease Progression; D004351:Drug Resistance; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000009:adverse effects; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D039981:Pyroglyphidae; D012074:Remission Induction; D055815:Young Adult
chemical_list: D039741:Antigens, Dermatophagoides; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007073:Immunoglobulin E